FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine and aims at reducing the formation of fibrous tissue accompanying wound healing. Pharmaceutical composition is used which contains a therapeutic amount of a mitogen-activated protein kinase-activated protein kinase 2 (MK2) inhibitor with amino acid sequence FAKLAARLYRKALARQLGVAA (SEQ ID NO: 3) and a pharmaceutically acceptable carrier. Also disclosed is a method of treating skin tissue, substituted with fibrous tissue.
EFFECT: group of inventions allows reducing cases of skin tissue, substituted with fibrous tissue, or reducing the severity of this condition, without disturbing normal wound healing, and reducing at least one of the following: wound size, scar area and formation of collagen coils in the wound.
41 cl, 16 dwg, 12 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS FOR PREVENTION OR TREATMENT OF DISEASES, CONDITIONS, OR PROCESSES CHARACTERIZED BY ABERRANT FIBROBLAST PROLIFERATION AND EXTRACELLULAR MATRIX DEPOSITION | 2012 |
|
RU2620066C2 |
| NUCLEOTIDE SEQUENCE CODING FUSED PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN PDGFRA AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IGG4 | 2023 |
|
RU2821574C1 |
| METHOD OF TREATING GEFITINIB-RESISTANT CANCER | 2006 |
|
RU2405566C9 |
| HUMAN ANTIBODIES TO RECEPTOR OF EPIDERMAL GROWTH FACTOR | 2005 |
|
RU2402569C2 |
| CELL | 2016 |
|
RU2729158C2 |
| METHODS AND COMPOSITIONS APPLICABLE FOR MODULATION OF ANTIOGENESIS USING PROTEIN KINASES RAF AND RAS | 2000 |
|
RU2257911C2 |
| HUMAN RET-BINDING ANTIBODIES AND METHODS OF USE THEREOF | 2020 |
|
RU2821548C2 |
| METHOD OF IDENTIFICATION OF INHIBITORS OR AGONISTS OF PROTEIN KINASE IRS | 2004 |
|
RU2340898C2 |
| PEPTIDE PROTECTION AGAINST ULTRAVIOLET LIGHT TOXICITY | 2010 |
|
RU2565535C2 |
| METHODS OF REGULATING INFLAMMATION MEDIATORS AND PEPTIDES USED IN THEM | 2007 |
|
RU2429004C2 |
